Spanish Biotech Platform
Plataforma de Mercados Biotecnológicos
Bionaturis unveils the development of six new biotech products
-Five of these new drugs point to Animal Health sector that represents a $100 billion global annual worldwide market
- Bionaturis Group strengthens its position as a reference partner for animal health
Bionaturis Group (ticker BNT) has recently unveiled up to six new biotech developments broadening its products portfolio, now accounting for more than twenty compounds in different developing stages for both human and animal health.
Five of these new products are devoted to veterinarian sector, pointing to several high-relevance diseases in livestock and pets, such as atopic dermatitis, osteoarthritis (or arthrosis) and different types of cancer, enhancing the Group position as a benchmark partner in the development of biological products for animal health.
The new unveiled products are:
BNT014 Tailored universal VLP-vaccine Prevention of common cold (rhinovirus) Humans Proof of concept in vivo
BNT015 Recombinant VPL Vaccine Viral infection Swine Proof of concept in vivo
BNT018 Recombinant VPL Vaccine Rabbit Hemorrhagic Fever Rabits Proof of concept in vivo
BNT020 Feline recombinant interferon omega (bio-better) Antiviral, antiproliferative, immunomodulatory Dogs and cats Proof of concept in vivo
BNT021 Low molecular weight antibody-like antagonist Atopic dermatitis, osteoarthitis Dogs, cats and horses Proof of concept
BNT022 Low molecular weight antibody-like antagonist Anti-cancer Dogs and cats Proof of concept
Animal Health sector, a growing market
According to “Global Animal Healthcare Market Size, Share, Development, Growth and Demand Forecast to 2020” report (by P&S Market Research) the global Animal Health sector represented an annual figure of $100 billion in 2014, being around $29 billion assigned to pharmaceutical products, feed additives and vaccines. The same report expects this segment to increase up to $44 billion by 2020, with a CAGR of 7.0%
The population growth and standard of living, resulting on a higher consumption of milk and meat and an increasing trend of adopting pets are some of the main robust drivers for the growth of the Animal Health market, which has nowadays a booming demand on both biological products and compounds devoted to reduce the use of traditional antibiotics
As opposed to the human sector, the developments in Animal Health require less investment and time and represent a low degree of uncertainty with a high R&D return of investment. At the same time, the role of third-party payers is very limited in this industry, so the interactions with the customers, the decision and also the payment is direct from them to the companies in the animal health industry.
The unveiled new medicines
It is noteworthy the significant increase of products addressed to pets (BNT020, BNT021 and BNT022) within the company portfolio, joining to the already known BNT005, a first-in-class vaccine with double effect (preventive and therapeutic) devoted to combat visceral canine leishmaniasis.
The pets market presents a healthy and steady growth being the United States the single largest pet market with a $58 billion global expenditure in 2014, where 68% of U.S. households have a pet (96 million of cats and 83 million of dogs; 85 million cats and 74 million dogs in Europe –source APPA). Only in the States, the market for canine osteoarthritis (the target market for BNT021) accounted for $260 million on sales in 2014, while $200 million were estimated for atopic dermatitis. About chemotherapy treatments (BNT022 target), the average cost in USA is between $2,500 and $10,000 per animal.
With these new developing products, Bionaturis Group enhances its position in one of the most lucrative sectors within Animal Health, presenting a clear value proposition for underserved diseases, species and markets.
About Bionaturis Group
Bionaturis Group offers cutting-edge biotechnological products and services for human and animal health, being considered an international benchmark in second generation vaccine developments. The biotechnological Group which envisages a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).
Related links: